[go: up one dir, main page]

FR3003871B1 - AURORA PROTEIN KINASE WITH MUTEE SENSITIVE TO INHIBITOR - Google Patents

AURORA PROTEIN KINASE WITH MUTEE SENSITIVE TO INHIBITOR

Info

Publication number
FR3003871B1
FR3003871B1 FR1352932A FR1352932A FR3003871B1 FR 3003871 B1 FR3003871 B1 FR 3003871B1 FR 1352932 A FR1352932 A FR 1352932A FR 1352932 A FR1352932 A FR 1352932A FR 3003871 B1 FR3003871 B1 FR 3003871B1
Authority
FR
France
Prior art keywords
mutee
inhibitor
sensitive
protein kinase
aurora protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1352932A
Other languages
French (fr)
Other versions
FR3003871A1 (en
Inventor
Claude Prigent
David Reboutier
Marie Berengere Troadec
Patrick Salaun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Rennes 1
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Rennes 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Rennes 1 filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR1352932A priority Critical patent/FR3003871B1/en
Priority to PCT/FR2014/050754 priority patent/WO2014155022A1/en
Publication of FR3003871A1 publication Critical patent/FR3003871A1/en
Application granted granted Critical
Publication of FR3003871B1 publication Critical patent/FR3003871B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR1352932A 2013-03-29 2013-03-29 AURORA PROTEIN KINASE WITH MUTEE SENSITIVE TO INHIBITOR Expired - Fee Related FR3003871B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR1352932A FR3003871B1 (en) 2013-03-29 2013-03-29 AURORA PROTEIN KINASE WITH MUTEE SENSITIVE TO INHIBITOR
PCT/FR2014/050754 WO2014155022A1 (en) 2013-03-29 2014-03-28 Inhibitor-sensitive mutated aurora a kinase protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1352932A FR3003871B1 (en) 2013-03-29 2013-03-29 AURORA PROTEIN KINASE WITH MUTEE SENSITIVE TO INHIBITOR

Publications (2)

Publication Number Publication Date
FR3003871A1 FR3003871A1 (en) 2014-10-03
FR3003871B1 true FR3003871B1 (en) 2015-04-24

Family

ID=49003825

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1352932A Expired - Fee Related FR3003871B1 (en) 2013-03-29 2013-03-29 AURORA PROTEIN KINASE WITH MUTEE SENSITIVE TO INHIBITOR

Country Status (2)

Country Link
FR (1) FR3003871B1 (en)
WO (1) WO2014155022A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127255C (en) * 2019-01-22 2024-01-16 Interax Biotech Ag Beta-arrestin mutants

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340475T3 (en) * 2002-05-01 2010-06-04 Vertex Pharmaceuticals Incorporated CRYSTALLIZED STRUCTURE OF AURORA-2 PROTEIN AND ITS UNION POCKETS.
WO2012068232A1 (en) * 2010-11-16 2012-05-24 Purdue Research Foundation Aurora a kinase effectors

Also Published As

Publication number Publication date
FR3003871A1 (en) 2014-10-03
WO2014155022A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
EP3985003C0 (en) DNA-PK INHIBITORS
HRP20181392T1 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE
LT3290407T (en) BROMODOMENE INHIBITORS
EP2969007A4 (en) HISTONDEMETHYLASE INHIBITORS
UA29014S (en) COMPUTER
BR302013002320S1 (en) TABLET TYPE COMPUTER CONFIGURATION
HUE037763T2 (en) Heterocyclic amides as kinase inhibitors
PT3052485T (en) HETEROCYCLIC COMPOUNDS AND THEIR USES
DK3321262T3 (en) Serine / threonine kinase inhibitors
EP2948458A4 (en) BTK INHIBITORS
DK2978844T3 (en) MODIFIED TGF-BETA2 OLIGONUCLEOTIDS
DK2971476T3 (en) DOUBLE MAGNETIC SENSOR ACTIVATOR
BR302013005760S1 (en) TABLET COMPUTER CONFIGURATION
EP2948431A4 (en) BTK INHIBITORS
DK3027249T3 (en) INJECTION PEN
DK2986611T3 (en) Specific protein kinase inhibitors
BR302013005762S1 (en) TABLET COMPUTER CONFIGURATION
ME02985B (en) AMINO-HINAZOLINE KINASE INHIBITOR PROTECTION
DK2978775T3 (en) Thermally modified starch
EP2987086A4 (en) SECURED COMPUTING
SG10201707478UA (en) Quorum sensing inhibitors
EP2999472A4 (en) INHIBITORS OF AURORA KINASE
DK3404203T4 (en) BOREHOLE LINING
EP3371659A4 (en) METRONIC SENSITIVE TO CONTACT
DK2881673T3 (en) Underfloor

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

ST Notification of lapse

Effective date: 20161130